ATYR

#5106
aTyr Pharma, Inc. - Common Stock
0.0 1 USD
-98.90%
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
0.01
0.01
Year Range
0.01
1.11
Daily Change
-98.90%
Monthly Change
-99.29%
6 month change
-99.44%
Year Change
-99.44%
Previous Close
0.4 9
Open
0.0 1
Low
0.0 1
High
0.0 1
Volume
30
Open full chart Full chart

Financials

Overview Statement Statistics
Quarterly Annual
Income statement Balance sheet Cash flow
Value 202020212022202320242025 TTM

aTyr Pharma, Inc. - Common Stock

aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases. The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease, a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients. The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla.